Zhi Tong Cai Jing·2025-11-19 13:19Core Viewpoint - Roche's Lunsumio (mosunetuzumab) subcutaneous injection has received conditional marketing authorization from the European Commission for the treatment of adult patients with relapsed or refractory follicular lymphoma who have undergone at least second-line systemic therapy [1] Group 1: Product Approval - The subcutaneous formulation of mosunetuzumab is now approved for use in outpatient settings, significantly reducing administration time to just 1 minute compared to the 2-4 hours required for the intravenous formulation [1] - The intravenous formulation of mosunetuzumab was previously approved in the EU in June 2022 [1] Group 2: Mechanism of Action - Mosunetuzumab is a bispecific T-cell engager that targets CD20 and CD3, activating and redirecting existing T-cells to release cytotoxic proteins into B-cells, thereby activating and eliminating target B-cells [1]